Wedbush Research Analysts Boost Earnings Estimates for APLS

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Stock analysts at Wedbush lifted their FY2025 earnings estimates for Apellis Pharmaceuticals in a research report issued on Tuesday, July 15th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($0.16) for the year, up from their previous forecast of ($0.22). The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals' Q4 2025 earnings at ($0.52) EPS.

APLS has been the topic of several other reports. Morgan Stanley increased their price target on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the company an "equal weight" rating in a report on Wednesday, July 2nd. Royal Bank Of Canada cut their price target on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating for the company in a research note on Thursday, May 8th. Bank of America upped their price target on shares of Apellis Pharmaceuticals from $23.00 to $24.00 and gave the company a "neutral" rating in a research report on Wednesday. Wells Fargo & Company raised their price objective on shares of Apellis Pharmaceuticals from $26.00 to $29.00 and gave the stock an "equal weight" rating in a report on Monday, June 2nd. Finally, Needham & Company LLC cut their target price on shares of Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Nine analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $39.84.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ:APLS opened at $19.75 on Thursday. The company has a debt-to-equity ratio of 2.76, a quick ratio of 3.62 and a current ratio of 4.08. The firm has a market cap of $2.48 billion, a price-to-earnings ratio of -11.03 and a beta of 0.67. The business has a 50-day simple moving average of $18.14 and a two-hundred day simple moving average of $22.81. Apellis Pharmaceuticals has a fifty-two week low of $16.10 and a fifty-two week high of $41.94.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The company had revenue of $149.90 million during the quarter, compared to analysts' expectations of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 99.19% and a negative net margin of 28.83%. The business's quarterly revenue was down 3.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.54) EPS.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 1,900 shares of the firm's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $20.09, for a total transaction of $38,171.00. Following the transaction, the chief executive officer directly owned 342,333 shares of the company's stock, valued at approximately $6,877,469.97. This trade represents a 0.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel David O. Watson sold 5,000 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $18.77, for a total value of $93,850.00. Following the transaction, the general counsel directly owned 133,730 shares in the company, valued at approximately $2,510,112.10. This represents a 3.60% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 144,365 shares of company stock worth $2,907,439. 6.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC lifted its position in shares of Apellis Pharmaceuticals by 119.6% during the 1st quarter. AQR Capital Management LLC now owns 4,077,419 shares of the company's stock valued at $89,173,000 after acquiring an additional 2,220,977 shares during the period. Boxer Capital Management LLC purchased a new position in Apellis Pharmaceuticals in the 4th quarter valued at approximately $45,504,000. National Bank of Canada FI raised its holdings in Apellis Pharmaceuticals by 266,361.5% during the fourth quarter. National Bank of Canada FI now owns 1,385,600 shares of the company's stock worth $44,214,000 after purchasing an additional 1,385,080 shares during the last quarter. Royal Bank of Canada raised its holdings in Apellis Pharmaceuticals by 969.6% during the fourth quarter. Royal Bank of Canada now owns 1,518,827 shares of the company's stock worth $48,465,000 after purchasing an additional 1,376,832 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Apellis Pharmaceuticals during the fourth quarter worth $40,461,000. 96.29% of the stock is currently owned by institutional investors and hedge funds.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.